OBESITY has steadily emerged as a significant public health concern in the Philippines with increasing prevalence over the past decades. It used to be a concern among the high-income group but it has ...

ByInvesting.com • May 22, 2025 New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect Today ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

Forbes contributors publish independent expert analyses and insights. Tima Bansal is an award-winning professor of strategy.

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...